1st participant dosed in important new Xanamem study-XanaHES

Thursday, February 21, 2019 9:00 PM +00:00

1st participant dosed in important new Xanamem study-XanaHES0:0014:20
LIVEQuality1  AudioSubtitleDownloadSpeed1  
ACTINOGEN LIMITED
Bill Ketelbey

Actinogen Medical (ASX: ACW) is pleased to announce dosing of the first participant in XanaHES, a Phase I dose escalation safety study of Xanamem in healthy elderly volunteers. XanaHES is designed to expand the safety data-set for Xanamem, while exploring the potential for higher doses of the drug to be used, if considered necessary, in future trials in Alzheimer's disease and other indications. It is planned that 42 participants will be randomised into the first cohort and receive either 20mg Xanamem or placebo daily for 12 weeks. Following a review of the 20mg safety data, a second cohort of 42 participants may be randomised to receive 30mg Xanamem or placebo daily.


Leave a Comment

Your email address will not be published

EVENTS Calendar

No broadcasts found.